Menopause medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 12: Line 12:


*The most effective [[treatment]] of severe [https://www.mayoclinic.org/diseases-conditions/menopause/symptoms-causes/syc-20353397 menopausal symptoms] is [[hormone therapy|hormonal replacement therapy]] ([[TRH]]), it used to treat [https://www.contemporaryobgyn.net/view/managing-menopause-part-1-vasomotor-symptoms vasomotor symptoms], [[osteoporosis]], prevent [[genitourinary]] [[atrophy]] and [[sleep disturbances]]. The [[Hormone|HRT]] includes [[estrogens]], [[progesterone]] and other [[hormones]] that are administered to compensate for [[hormone]] deficiency in a [[menopausal]] woman's body.
*The most effective [[treatment]] of severe [https://www.mayoclinic.org/diseases-conditions/menopause/symptoms-causes/syc-20353397 menopausal symptoms] is [[hormone therapy|hormonal replacement therapy]] ([[TRH]]), it used to treat [https://www.contemporaryobgyn.net/view/managing-menopause-part-1-vasomotor-symptoms vasomotor symptoms], [[osteoporosis]], prevent [[genitourinary]] [[atrophy]] and [[sleep disturbances]]. The [[Hormone|HRT]] includes [[estrogens]], [[progesterone]] and other [[hormones]] that are administered to compensate for [[hormone]] deficiency in a [[menopausal]] woman's body.
*There are several types of [[Therapy|therapies]] such as [https://www.mayoclinic.org/tests-procedures/combination-birth-control-pills/about/pac-20385282#:~:text=Combination%20birth%20control%20pills%2C%20also,sperm%20from%20joining%20the%20egg. combined oral contraceptives], [https://www.mayoclinic.org/diseases-conditions/menopause/in-depth/hormone-therapy/art-20046372#:~:text=Systemic%20estrogen%20%E2%80%94%20which%20comes%20in,Low%2Ddose%20vaginal%20products. systemic estrogen], [https://www.aafp.org/afp/2016/0215/p307.html estrogen-bazedoxifene], [https://medlineplus.gov/druginfo/meds/a601041.html estrogen-progestin], [[progestin]] alone, and [https://www.sciencedirect.com/science/article/abs/pii/S0960076013002045 conjugated equine estrogens]([[Premarin]]). It is should be used for a short duration and the lowest [[effective dose]] and can be given in various forms ([[tablets]], [[Cream (pharmaceutical)|creams]], patches), in different modalities (continuous or cyclic).<ref name="pmid26348174">{{cite journal| author=Kaunitz AM, Manson JE| title=Management of Menopausal Symptoms. | journal=Obstet Gynecol | year= 2015 | volume= 126 | issue= 4 | pages= 859-876 | pmid=26348174 | doi=10.1097/AOG.0000000000001058 | pmc=4594172 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26348174  }} </ref><ref name="pmid26348174">{{cite journal| author=Kaunitz AM, Manson JE| title=Management of Menopausal Symptoms. | journal=Obstet Gynecol | year= 2015 | volume= 126 | issue= 4 | pages= 859-876 | pmc=4594172 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26348174 }} </ref>
*There are several types of [[Therapy|therapies]] such as [https://www.mayoclinic.org/tests-procedures/combination-birth-control-pills/about/pac-20385282#:~:text=Combination%20birth%20control%20pills%2C%20also,sperm%20from%20joining%20the%20egg. combined oral contraceptives], [https://www.mayoclinic.org/diseases-conditions/menopause/in-depth/hormone-therapy/art-20046372#:~:text=Systemic%20estrogen%20%E2%80%94%20which%20comes%20in,Low%2Ddose%20vaginal%20products. systemic estrogen], [https://www.aafp.org/afp/2016/0215/p307.html estrogen-bazedoxifene], [https://medlineplus.gov/druginfo/meds/a601041.html estrogen-progestin], [[progestin]] alone, and [https://www.sciencedirect.com/science/article/abs/pii/S0960076013002045 conjugated equine estrogens]([[Premarin]]). It is should be used for a short duration and the lowest [[effective dose]] and can be given in various forms ([[tablets]], [[Cream (pharmaceutical)|creams]], patches), in different modalities (continuous or cyclic).<ref name="pmid26348174">{{cite journal| author=Kaunitz AM, Manson JE| title=Management of Menopausal Symptoms. | journal=Obstet Gynecol | year= 2015 | volume= 126 | issue= 4 | pages= 859-876 | pmid=26348174 | doi=10.1097/AOG.0000000000001058 | pmc=4594172 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26348174  }} </ref><ref name="pmid22367731">{{cite journal| author=North American Menopause Society| title=The 2012 hormone therapy position statement of: The North American Menopause Society. | journal=Menopause | year= 2012 | volume= 19 | issue= 3 | pages= 257-71 | pmid=22367731 | doi=10.1097/gme.0b013e31824b970a | pmc=3443956 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22367731  }} </ref><ref name="pmid15495039">{{cite journal| author=Maclennan AH, Broadbent JL, Lester S, Moore V| title=Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. | journal=Cochrane Database Syst Rev | year= 2004 | volume= | issue= 4 | pages= CD002978 | pmid=15495039 | doi=10.1002/14651858.CD002978.pub2 | pmc=7004247 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15495039 }} </ref>


====Selective Estrogen Receptor Modulators (SERMs)====
====Selective Estrogen Receptor Modulators (SERMs)====
Line 28: Line 28:
*[[Hormone therapy|Hormone replacement  therapy]] is [[Contraindication|contraindicated]] in women with a positive history of [[breast cancer]], [[endometrial cancer]], [[deep vein thrombosis]], [[pulmonary embolism]], [[Liver diseases|liver disease]], [https://www.healthline.com/health/dysfunctional-uterine-bleeding-dub dysfunction uterine bleeding], and [[coronary heart disease]] due to an increased risk of developing [[cancer]] after 3 to 7 years of using [[hormone therapy]].
*[[Hormone therapy|Hormone replacement  therapy]] is [[Contraindication|contraindicated]] in women with a positive history of [[breast cancer]], [[endometrial cancer]], [[deep vein thrombosis]], [[pulmonary embolism]], [[Liver diseases|liver disease]], [https://www.healthline.com/health/dysfunctional-uterine-bleeding-dub dysfunction uterine bleeding], and [[coronary heart disease]] due to an increased risk of developing [[cancer]] after 3 to 7 years of using [[hormone therapy]].
*Women who have had a [[hysterectomy]] seem to tolerate [[estrogen]]-only therapy better than mixed-[[hormone therapy]], and reduce the [[breast cancer]] risk brought on by [[progestin]] supplementation. The use of localized [[estrogen]] therapy ([https://www.webmd.com/menopause/qa/what-are-estrogen-replacement-therapy-vaginal-suppositories-rings-and-creams vaginal rings, creams, or tablets]), has been shown to enhance [[blood flow]] and reverse [[vaginal atrophy]] and carries a small risk of [[venous thromboembolism]].
*Women who have had a [[hysterectomy]] seem to tolerate [[estrogen]]-only therapy better than mixed-[[hormone therapy]], and reduce the [[breast cancer]] risk brought on by [[progestin]] supplementation. The use of localized [[estrogen]] therapy ([https://www.webmd.com/menopause/qa/what-are-estrogen-replacement-therapy-vaginal-suppositories-rings-and-creams vaginal rings, creams, or tablets]), has been shown to enhance [[blood flow]] and reverse [[vaginal atrophy]] and carries a small risk of [[venous thromboembolism]].
*[[Women]] had been advised for many years that [[hormone therapy]] after [[menopause]] might reduce their risk of [[heart disease]] and prevent various aspects of aging. However, a large, randomized, controlled trial (the [[Women's Health Initiative]]) found that women undergoing [[Hormone Replacement Therapy|HT]] with [https://www.sciencedirect.com/science/article/abs/pii/S0960076013002045 conjugated equine estrogens] ([[Premarin]]), whether or not used in combination with a [[progestin]] ([[Premarin]] plus [[Provera]]), had a slightly increased risk of [[breast cancer]], [[heart disease]], [[cerebrovascular accident|stroke]], and [[Alzheimer's disease]].
*[[Women]] had been advised for many years that [[hormone therapy]] after [[menopause]] might reduce their risk of [[heart disease]] and prevent various aspects of aging. However, a large, randomized, controlled trial (the [[Women's Health Initiative]]) found that women undergoing [[Hormone Replacement Therapy|HT]] with [https://www.sciencedirect.com/science/article/abs/pii/S0960076013002045 conjugated equine estrogens] ([[Premarin]]), whether or not used in combination with a [[progestin]] ([[Premarin]] plus [[Provera]]), had a slightly increased risk of [[breast cancer]], [[heart disease]], [[cerebrovascular accident|stroke]], and [[Alzheimer's disease]].
*After these results were reported in 2002, the number of [[prescriptions]] written for [[Premarin]]  in the United States dropped almost in half, as many [[women]] discontinued [[Hormone Replacement Therapy|HT]] altogether. The sharp drop in [[Prescription|prescriptions]] for [[Premarin]] and PremPro following the mid-2002 announcement of their dangers was followed by large and successively greater drops in new [[breast cancer]] diagnoses at six months, one year, and 18 months after that announcement, for a cumulative 15% drop by the end of 2003. And the studies still continue to determine if the drop is related to the reduced use of [[HRT]].
*After these results were reported in 2002, the number of [[prescriptions]] written for [[Premarin]]  in the United States dropped almost in half, as many [[women]] discontinued [[Hormone Replacement Therapy|HT]] altogether. The sharp drop in [[Prescription|prescriptions]] for [[Premarin]] and PremPro following the mid-2002 announcement of their dangers was followed by large and successively greater drops in new [[breast cancer]] diagnoses at six months, one year, and 18 months after that announcement, for a cumulative 15% drop by the end of 2003. And the studies still continue to determine if the drop is related to the reduced use of [[HRT]].<ref name="pmid14519708">{{cite journal| author=Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M | display-authors=etal| title=Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. | journal=JAMA | year= 2003 | volume= 290 | issue= 13 | pages= 1739-48 | pmid=14519708 | doi=10.1001/jama.290.13.1739 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14519708  }} </ref><ref name="pmid7824251">{{cite journal| author=Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D| title=Hormone replacement therapy and endometrial cancer risk: a meta-analysis. | journal=Obstet Gynecol | year= 1995 | volume= 85 | issue= 2 | pages= 304-13 | pmid=7824251 | doi=10.1016/0029-7844(94)00383-O | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7824251  }} </ref><ref name="pmid24084921">{{cite journal| author=Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL | display-authors=etal| title=Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. | journal=JAMA | year= 2013 | volume= 310 | issue= 13 | pages= 1353-68 | pmid=24084921 | doi=10.1001/jama.2013.278040 | pmc=3963523 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24084921  }}  [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=&cmd=prlinks&id=24492931 Review in: Evid Based Med. 2014 Jun;19(3):105] </ref>





Revision as of 05:55, 18 February 2021

Menopause Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differential Diagnosis

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Ultrasonography

Other Imaging Findings

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Menopause medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Menopause medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Menopause medical therapy

CDC on Menopause medical therapy

Menopause medical therapy in the news

Blogs on Menopause medical therapy

Directions to Hospitals Treating Menopause

Risk calculators and risk factors for Menopause medical therapy


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Rahmah Al-Edresi, M.D.[2]

Overview

While perimenopause is a natural stage of life when the symptoms are severe, this may be alleviated through medical treatments that include Hormone therapy(HT), non-hormonal therapy, and complementary or alternative therapies.Hormonal therapy (HT) provides the best relief, but hormone therapy should only be used for the shortest duration of time and at its lowest effective dose, as it increases the relative risk of uterine cancer ,ovarian cancer, breast cancer, thromboembolism, and coronary heart disease, especially in women who start HT after menopause. Some other drugs afford limited relief from hot flashes. A woman and her doctor should carefully review her symptoms and relative risk before determining whether the benefits of HT or other therapies outweigh the risks.

Medical therapy

Hormonal replacement therapy(HRT)

Selective Estrogen Receptor Modulators (SERMs)

Other forms of hormone therapy:

Adverse effects:


Non Hormonal therapy:

Non hormonal therapy includes serotonin-norepinephrine reuptake inhibitors(SNRIs), selective serotonin reuptake inhibitors (SSRIs), clonidine, and gabapentin.

Complementary and alternative therapies:

Other therapies:

  • Individual counseling or support groups may be helpful to handle sad, depressed, or confusing feelings women may be having as their bodies change.
  • Vaginal moisturizers such as Vagisil or Replens and lubricants, such as K-Y Jelly or Astroglide can help women with thinning vaginal tissue, dryness, and decrease the pain that may be present during intercourse.
  • Moisturizers and lubricants are different products for different types of issues. Some women feel dry apart from sex and they may do better with moisturizers all the time. Those who just need lubricants are fine just using the lubrication products during intercourse. Low-dose vaginal estrogen is generally a safe way to take estrogen to solve vaginal thinning and dryness problems while only minimally increasing the levels of estrogen in the blood.
  • Drinking cold liquids and removing excess clothing layers when hot flashes strike, and avoiding hot flash triggers such as spicy foods maybe relieve some symptoms for some women.



References

  1. Kaunitz AM, Manson JE (2015). "Management of Menopausal Symptoms". Obstet Gynecol. 126 (4): 859–876. doi:10.1097/AOG.0000000000001058. PMC 4594172. PMID 26348174.
  2. North American Menopause Society (2012). "The 2012 hormone therapy position statement of: The North American Menopause Society". Menopause. 19 (3): 257–71. doi:10.1097/gme.0b013e31824b970a. PMC 3443956. PMID 22367731.
  3. Maclennan AH, Broadbent JL, Lester S, Moore V (2004). "Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes". Cochrane Database Syst Rev (4): CD002978. doi:10.1002/14651858.CD002978.pub2. PMC 7004247 Check |pmc= value (help). PMID 15495039.
  4. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M; et al. (2003). "Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial". JAMA. 290 (13): 1739–48. doi:10.1001/jama.290.13.1739. PMID 14519708.
  5. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D (1995). "Hormone replacement therapy and endometrial cancer risk: a meta-analysis". Obstet Gynecol. 85 (2): 304–13. doi:10.1016/0029-7844(94)00383-O. PMID 7824251.
  6. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL; et al. (2013). "Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials". JAMA. 310 (13): 1353–68. doi:10.1001/jama.2013.278040. PMC 3963523. PMID 24084921. Review in: Evid Based Med. 2014 Jun;19(3):105
  7. Bansal R, Aggarwal N (2019). "Menopausal Hot Flashes: A Concise Review". J Midlife Health. 10 (1): 6–13. doi:10.4103/jmh.JMH_7_19. PMC 6459071. PMID 31001050.


Template:WikiDoc Sources